What first drew you to thoracic oncology, and how has your research focus evolved?
My first position, as an oncologist, was in thoracic oncology. I had a wonderful mentor who completely changed my view of the disease, and that inspired me to continue my career in thoracic oncology.
Lung cancer, the most common thoracic tumour, is the leading cause of cancer mortality worldwide. Over the years, we have seen substantial progress in understanding its aetiology and its molecular and immune pathways, which has supported the clinical development of new therapies. It is a field where we can see the impact of translational research from bench to bedside.
My research is somewhat different from that of many other thoracic oncologists, because much of my focus is on cancer prevention and environmental exposures, and how these environmental exposures can impact patients with cancer.
I was inspired to pursue this area of research by a young patient I treated in my first position as a lung cancer oncologist. From that experience, I learnt about the risk of radon exposure in our homes, which is one of the leading causes of lung cancer in people who have never smoked. She was a 40-year-old, had never smoked, and had adenocarcinoma with an EGFR mutation. I decided to read more about the subject and, little by little, became involved in research. This eventually became the focus of my PhD, during which I measured radon in the homes of patients.
My focus is not to demonstrate that radon, air pollution, genetics, or other risk factors beyond smoking are associated with lung cancer. We already know this from epidemiological studies. Instead, I am trying to understand how these risk factors can influence tumour biology. This could help us to define populations at risk, improve cancer prevention and patient care, and develop better treatments.
As Chair of the European Society of Medical Oncology (ESMO)’s Cancer Prevention and Interception Committee, what does your role involve, and what are your key priorities?
I started chairing the committee very recently, so I am continuing the work previously carried out by my colleagues, who focused on both cancer prevention and interception. I believe these are priorities for oncologists.
My priority is to improve education. We need to educate and train cancer specialists in cancer prevention, because, although we know a great deal about diagnosing the disease and what comes afterwards, we receive less training in prevention.
We also need to create stronger links between epidemiologists, prevention experts, and oncologist, because together we can better support risk assessment, cancer prevention, early detection, and screening.
One of my first priorities is to work on developing practical tools to collect information about risk factors in patient’s medical histories. In our daily practice, information beyond smoking is not always well documented. I think that, through ESMO, these tools could help ESMO members around the world.
How can oncologists do more to integrate cancer prevention and early detection into routine clinical care?
There is a lot that we can do for prevention. We can collect information in the medical history, not only on smoking, but also occupational and environmental factors, family history of cancer, and dietary risk factors.
We can also support primary prevention during consultations, including smoking cessation, not only for patients, but also for their families.
We can also promote screening. We are seeing more and more patients who have been cured of previous cancer, and we need to consider their risk of second primary cancers and encourage them to participate in appropriate screening programmes.
We can also do a lot outside the consultation, including supporting public health measures and tobacco control policies. These are not topics that should be left to other specialties. All cancer specialists should be involved, as prevention is part of our job.
With the ESMO Congress in Madrid, Spain, approaching, which thoracic oncology studies or emerging themes should clinicians be watching most closely?
There will be a lot of new data presented at ESMO. The results from the Presidential Sessions could be among the most exciting. For a long time, treatment options for small-cell lung cancer have been limited, and now we will see new data in the maintenance setting. This is an area where we hope to see results that could change clinical practice.
We also hope to see interesting data in the setting of treatment resistance, including how precision medicine and drug combinations can improve outcomes for patients with EGFR mutations. In the KRAS-mutated population, which was previously considered difficult to target, we may also see newer generations of drugs changing clinical practice.
What do you consider the most significant advancement in thoracic oncology this year, and how could it change clinical practice?
The data that will be presented at ESMO on small-cell lung cancer may represent one of the most significant advances. This is one of the most aggressive and difficult-to-treat types of thoracic cancer.
Approximately 10–15% of lung cancer cases are small-cell lung cancer. It is not the most common type, but it is associated with a very poor prognosis. Demonstrating a benefit with new types of treatment is therefore particularly important and could open up a new era for this disease.
What are the biggest remaining challenges in predicting immunotherapy response and overcoming treatment resistance in lung cancer?
One of the main gaps is that we have very effective drugs, but only a proportion of patients achieve long-term benefit, and we are not yet good enough at identifying who these patients will be.
In lung cancer, we have programmed death-ligand 1 (PD-L1), but this is not sufficient on its own as a biomarker. It helps identify a population more likely to respond, but not all patients with PD-L1-positive tumours will have the response we hope to see.
I think the challenge is to improve prediction by integrating tumour biomarkers with host-related biomarkers and clinical factors. Using all this information together to develop tools that can better predict outcomes is a major challenge for the future of immunotherapy.
What breakthrough would you most like to see in lung cancer prevention or treatment over the next 5 years?
I would like to see lung cancer screening and prevention become more accessible and effective. We should work to ensure that lung cancer screening is implemented in countries where it is not yet available, and that it becomes more accessible in countries where it is already in place.
We need to overcome the barriers that prevent people from participating in lung cancer screening, particularly educational barriers. This is important both in areas where screening is being implemented and in countries such as Spain, where screening initiatives are underway and further work is needed towards implementation within the national healthcare system.
In addition to early detection, we need to focus on primary prevention and raise awareness not only about smoking, but also about other risk factors and exposures, such as vaping, cannabis use, radon, and other environmental and occupational exposures.
We also need to improve the quality of lung cancer screening programmes. One important goal I would like to see achieved in the next 5 years is a better ability to identify high-risk populations. Current screening criteria still fail to identify some people at risk, including some women and younger people.
If we can improve risk assessment and develop better risk prediction models, we could detect these tumours earlier and increase the chances of curing the disease.





